Business
Bank of America Lifts Target on Xencor Amid Broader Biotech Sector Optimism
Bank of America has raised its price target for clinical-stage biopharma firm Xencor (XNCR), highlighting a cautiously improving landscape for the sector driven by data catalysts, M&A, and capital access.